BioSyent Keeps Momentum Going with Solid Q2 Earnings


BioSyent (TSXV:RX) today announced Q2 results that are indicative of the revenue and earnings momentum investors have to come to expect from this emerging specialty pharma company based in Ontario. As I have written previously in Cantech, I believe BioSyent is carving a path that is very similar to another Canadian specialty pharma success story […]

Antibe Therapeutics could shake up the NSAID market, says M Partners

While popular in both generic and prescription forms, NSAID such as Pfizer's arthritis treatment Celebrex have been known to cause small intestinal damage and bleeding.

Tiny Antibe Therapeutics (TSXV:ATE) may be set to shake up the massive NSAID market, says M Partners analyst Daniel Pearlstein. In a research report to clients yesterday, Pearlstein initiated coverage of Antibe Therapeutics with a “Buy” rating and a one-year target of $1.30, implying a 160% return at the time of publication. Pearlstein notes that […]

Prometic Life Sciences offers compelling risk/reward scenario, says Paradigm


ProMetic Life Sciences (TSX:PLI) offers a truly compelling risk/reward scenario, says Paradigm Capital analyst Alan Ridgeway. Last Thursday, ProMetic reported its Q2, 2014 results. The company posted revenue of $4.4-million, but delivered a net profit of $23.4-million due to the recognition of a gain on revaluation of the equity investment of its equity interest in […]

IMRIS is still undervalued, says Paradigm

At the Health Sciences Centre in Winnipeg last September, IMRIS introduced the the first VISIUS® Surgical Theatre in Canada that features both intraoperative MRI (iMRI) and angiography capability together in one three-room suite.

An overdue capital refresh cycle at hospitals is a likely catalyst for medical imaging leader IMRIS (TSX:IM), says Paradigm Capital analyst Alan Ridgeway. On Friday, IMRIS reported its second quarter, 2014 results. The company lost (US) $7.02-million on revenue of $4.3-million. The topline was down 58% from the $10.2-million the company delivered in the same […]

Halifax Biomedical To Participate in Horizon Health Network Lower Back Study


Horizon Health Network, the largest healthcare organization in Atlantic Canada, has announced the undertaking of a research study involving spine instability measurement technology developed by Halifax Biomedical Inc. (HBI). “At present, in some patients, there is a gap between patient symptoms and true abnormalities which can be identified with routine testing techniques including x-ray and […]

Tekmira’s TKM-Ebola treatment cleared by the FDA for use in worst outbreak ever


After being halted today at the market close, Tekmira (TSX:TKM) announced that the FDA had verbally confirmed it had modified the full clinical hold placed on its TKM-Ebola treatment, in light of the worst outbreak of the disease ever. Shares of the company are up more than 8% on the Nasdaq after-market. “We are pleased […]

TS03 Shares Spike On Anticipation of FDA Approval

TS03's low-temperature 125 litre STERIZONE® sterilizer is designed for terminal sterilization of heat and moisture sensitive medical devices.

Shares of Quebec City based TSO3 (TSX:TOS), surged yesterday after their earnings call left investors optimistic that an arduous 4-year wait for FDA clearance for the company’s ozone-based sterilizer might finally be near. The stock had been steadily moving upwards after a press release a few weeks ago announcing that FDA had asked the company […]

What does BioMarin’s voucher sale mean to Knight Therapeutics?

Mullally: How will investors react to news that BioMarin has sold its FDA priority review voucher for $67.5 million?  Perhaps investors should focus on the supply of vouchers rather than the price.

Today BioMarin (NASDAQ:BRMN) announced it had sold its FDA priority review voucher to Regeneron (NASDAQ:REGN) for US$67.5 million. Regeneron and its partner Sanofi plan to share the cost of the voucher and use it for their Biologics License Application (BLA) submission for their dyslipidemia product, alirocumab. The voucher grants the holder an expedited-review with FDA, […]

Investors awaken to the potential of newly focused Bioniche Life Sciences


Shares of Bioniche Life Sciences (TSX:BNC) have surged since the company a few weeks ago announced that the FDA agreed to accept a Biological License Application (BLA) for the potential approval of their immunotherapy product Urocidin. Today, the company announced it is making an orphan drug application for Urocidin with FDA, a move to gain […]

Allergan is a “free option” for investors looking at Valeant, says Paradigm

Paradigm Capital analyst Alan Ridgeway believes that Valeant Pharmaceuticals is an "acquisition-focused material growth opportunity".

Valeant Pharmaceuticals’ (TSX:VRX) upcoming Q2 may be the first of a number of quarters that show that the company’s acquisition-focused growth strategy is strong and sustainable, says Paradigm Capital analyst Alan Ridgeway. On Thursday, Valeant will report its Q2, 2014 results. The company is following up on a Q1 in which it posted a topline […]